1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Oragenics, Inc.
  6. Summary
    OGEN   US6840233026

ORAGENICS, INC.

(OGEN)
  Report
Delayed Nyse  -  04:00 2022-06-27 pm EDT
0.3150 USD   -1.56%
06/23ORAGENICS : Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer - Form 8-K
PU
06/23ORAGENICS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
06/23Oragenics Appoints Kimberly Murphy as President, CEO
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/21/2022 06/22/2022 06/23/2022 06/24/2022 06/27/2022 Date
0.2994(c) 0.3(c) 0.295(c) 0.32(c) 0.315(c) Last
291 845 257 549 250 650 435 346 230 491 Volume
-6.44% +0.20% -1.67% +8.47% -1.56% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -21,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,66x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -21,4 M - -
Net Debt 2023 - - -
P/E ratio 2023 -1,75x
Yield 2023 -
Capitalization 36,7 M 36,7 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 5
Free-Float 96,1%
More Financials
Company
Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including coronaviruses and multidrug-resistant organisms. The Company's lead product, NT-CoV2-1, is an intranasal immunization vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. Its other product candidates include Terra CoV-2 and Antibiotics. Terra CoV-2 is an intramuscular vaccine candidate... 
More about the company
All news about ORAGENICS, INC.
06/23ORAGENICS : Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Exe..
PU
06/23ORAGENICS INC : Change in Directors or Principal Officers, Financial Statements and Exhibi..
AQ
06/23Oragenics Appoints Kimberly Murphy as President, CEO
MT
06/23Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Ex..
BU
06/23Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer
CI
06/23Oragenics, Inc. Appoints Kimberly M. Murphy as President
CI
06/14Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 ..
BU
06/14Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 ..
CI
05/17ORAGENICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/17Oragenics Issues Letter to Shareholders
BU
05/13ORAGENICS : Q1 Earnings Snapshot
AQ
05/13ORAGENICS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/13Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/19ORAGENICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
04/18Oragenics to Participate at the World Vaccine Congress Washington 2022
BU
More news
News in other languages on ORAGENICS, INC.
06/23Oragenics nomme Kimberly Murphy au poste de présidente et de PDG
06/23Oragenics, Inc. nomme Kimberly M. Murphy au poste de directeur général
06/23Oragenics, Inc. nomme Kimberly M. Murphy au poste de présidente
06/14Oragenics annonce la publication de données positives pour son candidat vaccin intranas..
05/13Oragenics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
More news
Chart ORAGENICS, INC.
Duration : Period :
Oragenics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORAGENICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,32 $
Average target price 2,00 $
Spread / Average Target 535%
EPS Revisions
Managers and Directors
Kimberly M. Murphy President, Chief Executive Officer & Director
Michael O'Keefe Sullivan Chief Financial Officer, Secretary & Treasurer
Frederick W. Telling Executive Chairman
Robert C. Koski Independent Director
Charles L. Pope Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ORAGENICS, INC.-28.25%37
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-12.75%44 742
BIONTECH SE-48.01%32 574